Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe

Clinical Pharmacokinetics

Volumn 48, Issue 1, 2009, Pages 39-50

  Yu, Rosie Z ^a   Geary, Richard S ^a   Flaim, Joann D ^a   Riley, Gina C ^a   Tribble, Diane L ^a   VanVliet, André A ^b   Wedel, Mark K ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b PRA Health Sciences   (Netherlands)

Author keywords

Antisense oligonucleotides, drug interactions; Cholesterol absorption inhibitors, drug interactions; Drug interactions; Ezetimibe, drug interactions; HMG CoA reductase inhibitors, drug interactions; Mipomersen sodium, drug interactions; Pharmacokinetics

Indexed keywords

ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; EZETIMIBE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; METFORMIN; MIPOMERSEN; ROSIGLITAZONE; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LIVER CELL; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; AZETIDINES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; SIMVASTATIN;

EID: 57449103966     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/0003088-200948010-00003     Document Type: Article

References (38)

1. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114 (16): 1729-35
2. Kastelein J, Akdim F, Trip M. ISIS 301012, an antisense inhibitor of apolipoprotein B, produces significant additional reduction of low-density lipoprotein cholesterol and apolipoprotein B in hypercholesterolemic subjects on statins not meeting target [abstract no. 820-7]. J Am Coll Cardiol 2007, 49 (9 Suppl. A) 393A
3. Stein E, Wedel M, Bradley J. Statin-like, dose-dependent reductions in LDL cholesterol and apolipoprotein B with ISIS 301012, an antisense inhibitor of apolipoprotein B, in subjects with polygenic hypercholesterolemia [abstract no. 1206-278]. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 333A
4. Stein E. High low-density lipoprotein cholesterol on three drugs [abstract no. 603-8]. Common Challenges in Preventive Cardiology Symposium, 56th Scientific Session of the American College of Cardiology; 2007 Mar 24-27; New Orleans (LA)
5. Yu RZ, Kim T-W, Hong A, et al. Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human apoB-100. Drug Metab Dispos 2007; 35: 460-8
6. Geary RS, Ushiro-Watanabe T, Truong L, et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001; 296 (3): 890-7
7. Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31 (11): 1419-28
8. Yu RZ, Geary RS, Monteith DK, et al. Tissue disposition of a 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharmaceutical Sci 2004; 93: 48-59
9. Gaus HJ, Owens SR, Winniman M, et al. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 1997; 69 (3): 313-9
10. Phillips JA, Craig SJ, Bayley D, et al. Pharmacokinetics, metabolism and elimina- tion of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 1997; 54 (6): 657-68
11. Grundy JS, Yu RZ, Geary RS, et al. Comparative single-dose disposition of radiolabeled ISIS 104838 and ISIS 113715 in rat. Annual Meeting of Pharmaceutical Scientists; 2002 Nov 10-14; Toronto
12. Data on file, Isis Pharmaceuticals, Inc., 2007
13. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44 (9): 1054-62
14. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44 (5): 467-94
15. OECD principles on good laboratory practice. Paris: OECD, 1998 [online]. Available from URL: http://www.olis.oecd.org/olis/1998doc.nsf/LinkTo/env-mc- chem(98)17 [Accessed 2008 Oct 15]
16. Yu RZ, Baer B, Chappel A, et al. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determinalition of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 2002; 304 (1): 19-25
17. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000; 17 (12): 1551-7
18. US FDA Center for Drug Evaluation and Research. Guidance for industry: bioanalytical method validation. Rockville (MD): US FDA, 2001 [online]. Available from URL: http://www.fda.gov/CDER/GUIDANCE/4252fnl.htm [Accessed 2008 Oct 15]
19. Sewell LK, Geary RS, Baker BF, et al. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002; 303 (3): 1334-43
20. US FDA Center for Drug Evaluation and Research. Guidance for industry: E6 good clinical practice: consolidated guidance. Rockville (MD): US FDA, 1996 [online]. Available from URL: http://www.fda.gov/cder/guidance/959fnl.pdf [Accessed 2008 Nov 21]
21. US FDA Center for Drug Evaluation and Research. Guidance for industry: in vivo drug metabolism/drug interaction studies: study design, data analysis, and recommendations for dosing and labeling, Rockville (MD): US FDA, 1999 [online]. Available from URL: http://www.fda.gov/CbER/gdlns/metabol.htm [Accessed 2008 Oct 15]
22. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clinical Pharmacol Ther 1998; 64 (2): 177-82
23. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000; 68 (4): 384-90
24. Lohitnavy M, Lohitnavy O, Chaijittiprasert K, et al. Bioequivalence study of two formulations of simvastatin tablets in healthy Thai volunteers. Arzneimittelforschung 2004; 54 (1): 31-4
25. Zetia® (ezetimibe) tablets [package insert]. North Wales (PA): Merck/Schering-Plough Pharmaceuticals, 2001, 2002
26. Reyderman L, Kosoglou T, Statkevich P, et al. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther 2004; 42 (9): 512-8
27. Kedderis GL, Held SD. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactive and hepatic dosimetry in rats, mice, and humans. Toxicol Appl Pharmacol 1996; 140: 124-30
28. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten(country panel. J Intern Med 2006; 259 (3): 247-58
29. Watanabe TA, Geary RS, Riley-McMullen GC, et al. In vitro protein binding evaluation of an antisense oligonucleotide, mipomersen, targeting human apolipoprotein B-100. National Biotechnology Conference, American Association of Pharmaceutical Scientists; 2008 Jun 22-25; Toronto
30. Geary RS, Bradley JD, Watanabe T, et al. Lack of pharmacokinetic interaction for ISIS 113715, a 2′-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet 2006; 45 (8): 789-801
31. Adjei AA, Dy GK, Erlichman C, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003; 9 (1): 115-23
32. Villalona-Calero MA, Ritch P, Figueroa JA, et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10 (18 Pt 1): 6086-93
33. Motl SE. LY900003: a novel compound for the treatment of non-small cell lung cancer. Cancer Ther 2003; 1: 237-44
34. Geary RS, Leeds JM, Fitchett J, et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 1997; 25 (11): 1272-81
35. Yu RZ, Geary RS, Leeds JM, et al. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 2001; 90 (2): 182-93
36. Glover JM, Leeds JM, Mant TG, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282 (3): 1173-80
37. Brown DA, Kang SH, Gryaznov SM, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994; 269 (43): 26801-5
38. Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006; 16 (2): 169-80